Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Parent P, Auclin E, Patrikidou A, Mezquita L, Martínez Chanzá N, Dumont C, Rodriguez-Vida A, Llacer C, Lozano R, Ratta R, Merseburger AS, Sternberg CN, Baciarello G, Colomba E, Fuerea A, Besse B, Loriot Y, Lavaud P. Parent P, et al. Among authors: lavaud p. Cancers (Basel). 2023 Feb 7;15(4):1066. doi: 10.3390/cancers15041066. Cancers (Basel). 2023. PMID: 36831409 Free PMC article.
Atezolizumab in urothelial bladder carcinoma.
Hamilou Z, Lavaud P, Loriot Y. Hamilou Z, et al. Among authors: lavaud p. Future Oncol. 2018 Feb;14(4):331-341. doi: 10.2217/fon-2017-0433. Epub 2017 Nov 14. Future Oncol. 2018. PMID: 29135284 Review.
Durvalumab in urothelial cancers.
Lavaud P, Hamilou Z, Loriot Y, Massard C. Lavaud P, et al. Expert Rev Anticancer Ther. 2018 Apr;18(4):311-318. doi: 10.1080/14737140.2018.1443812. Epub 2018 Mar 5. Expert Rev Anticancer Ther. 2018. PMID: 29486607 Review.
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, Walz J, Pignot G, Rybikowski S, Dermeche S, Thomassin J, Brunelle S, Lavaud P, Loriot Y; French Genito-Urinary Tumor Group (GETUG). Gravis G, et al. Among authors: lavaud p. Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11. Eur J Cancer. 2018. PMID: 30316610 No abstract available.
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B. Flippot R, et al. Among authors: lavaud p. J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18. J Thorac Oncol. 2019. PMID: 31108248 Free article.
[Management of metastatic testicular germ cell tumors].
Lavaud P, Baciarello G, Fizazi K. Lavaud P, et al. Bull Cancer. 2019 Oct;106(10):896-902. doi: 10.1016/j.bulcan.2019.05.004. Epub 2019 Aug 26. Bull Cancer. 2019. PMID: 31466695 Review. French.
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS. Gómez de Liaño Lista A, et al. Among authors: lavaud p. Eur Urol. 2020 Feb;77(2):269-276. doi: 10.1016/j.eururo.2019.10.004. Epub 2019 Nov 5. Eur Urol. 2020. PMID: 31699525
83 results